KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Aquestive Therapeutics (AQST) Leases (2019 - 2025)

Aquestive Therapeutics (AQST) has 7 years of Leases data on record, last reported at $4.6 million in Q4 2025.

  • For Q4 2025, Leases fell 10.83% year-over-year to $4.6 million; the TTM value through Dec 2025 reached $4.6 million, down 10.83%, while the annual FY2025 figure was $4.6 million, 10.83% down from the prior year.
  • Leases reached $4.6 million in Q4 2025 per AQST's latest filing, down from $4.8 million in the prior quarter.
  • Across five years, Leases topped out at $5.9 million in Q1 2023 and bottomed at $2.1 million in Q3 2022.
  • Average Leases over 5 years is $4.4 million, with a median of $5.0 million recorded in 2025.
  • Peak YoY movement for Leases: fell 28.21% in 2022, then soared 170.73% in 2023.
  • A 5-year view of Leases shows it stood at $2.7 million in 2021, then skyrocketed by 91.23% to $5.2 million in 2022, then grew by 6.64% to $5.6 million in 2023, then fell by 6.75% to $5.2 million in 2024, then dropped by 10.83% to $4.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $4.6 million in Q4 2025, $4.8 million in Q3 2025, and $4.9 million in Q2 2025.